

**Thursday, 24 May 2018**

13.00-13.30	<b>Opening of the EUFEPS 2018</b> Erem Bilensoy, EUFEPS President, Conference Co_Chair Panos Macheras, EUFEPS Senator, Conference Co-Chair	
13.30-14.00	<b>PL-1 Stefan Knapp, Germany, "Novel Molecular Targets"</b>	
14.00-14.30	<b>PL-2 Mansoor Khan, US "Innovations and Nanomedicines: Balancing Responsible Science with Regulations for Success"</b>	
14.30-15.00	<b>PL-3 Jukka Rantanen, Denmark, "Manufacturing of Personalized Medicines"</b>	
15.00-15.30	<b>Coffee break and Poster Session-1</b>	
<b>Parallel sessions I</b>		
15.30-17.00	<b>Physiology of the GI tract relevant for drug absorption</b>	<b>Nanomedicines and nanosimilars: How to assess how similar?</b> <i>Organized by EUFEPS Nanomedicine Network</i>
15.30-16.00	<b>IL-1 Patrick Augustijns, Belgium</b> "Intestinal drug absorption: What do we know and what should we understand better?"	<b>IL-4 Gerrit Borchard, Switzerland</b> "Bench to Mensch and back: Identifying critical quality attributes for nanomedicines"
16.00-16.30	<b>IL-2 Martin Brandl, Denmark</b> "Colloidal structures and drug absorption: from amorphous nanoparticles to bile salt micelles"	<b>IL-5 Beatriz Silva Lima, Portugal</b> "Regulator's point of view for nanomedicines and nanosimilars"
16.30-17.00	<b>IL-3 Panos Macheras, Greece</b> "Do we need to consider a reaction limited in Vivo drug dissolution model?"	<b>OP-1 Beat Flühmann, Switzerland</b> "What is the cost of lacking regulatory clarity for nanosimilars?" <b>OP-2 Stefan Mühlebach, Switzerland</b> "Complex drugs: Challenges in selecting nanomedicines and their follow-on versions for a drug formulary"
17.00-18.15	<b>Flash oral presentations</b> <p style="text-align: center;"> <b>FP-1 Daniel Sironi, Denmark</b> "Assessing the performance of an amorphous solid dispersions with the novel dissolution/permeation setup Permaloop"  <b>FP-2 Ardita Veseli, Slovenia</b> "Simple thermodynamic BSC solubility with 5 mg tested compound"  <b>FP-3, Emre Şefik Çağlar, Turkey</b> "Preparation, optimization and in vitro-in vivo evaluation of voriconazole loaded topical mats of Poly(lactic acid)/Poly(ethylene succinate) blends for skin infections"  <b>FP-4 Eireini Christodoulou, Greece</b> "Serum and tissue pharmacokinetics of saffron aqueous extract after i.v. and peros administration to C5/BL6J mice"  <b>FP-5 Diego Perinelli, Italy</b> "In vitro and in vivo investigation of N-acyl amino based surfactants as permeability enhancers"  <b>FP-6 Nazlı Erdoğan, Turkey</b> "Novel anionic and cationic polymeric nanocapsules for oral delivery of docetaxel: preparation, in vitro and in vivo evaluation"                 </p> <p style="text-align: center;"> <b>EUFEPS Networks Panel</b>                      EPRIN, Ana Alfirevic                      QbD PAT, Jukka Rantanen                      Veterinary Sciences, Ivo Schmerold                      Systems Pharmacology, Meindert Danhof                      Nanomedicine, Erem Bilensoy                      BABP, Werner Weitschies                 </p>	
19.00-21.00	<b>Opening ceremony and welcome reception</b> <b>Venue: University Rectorate Building under the patronage of Rector of University of Athens</b>	

**Friday, 25 May 2017**

09.00- 09.30	<b>PL-4 Leslie Benet, US “Calculating extraction ratios and predicting IVIVE: The unrecognized assumptions”</b>	
09.30-10.00	<b>PL-5 The Douwe Breimer Lecture, Per Artursson, Sweden “Intracellular drug bioavailability: a new predictor of transport and metabolism dependent drug disposition and intracellular target engagement.”</b>	
10.00-10.30	<b>Coffee break and Poster Session-2</b>	
<b>Parallel sessions II</b>		
	<b>Performance of dosage forms in the body and impact on drug absorption</b>	<b>Nanomedicines: Challenges on the road</b> <i>Organized by EUFEPS Nanomedicine Network</i>
10.30-11.00	<b>IL-6 Werner Weitschies, Germany</b> “GI physiology vs. formulation technology: who is in the driving seat?”	<b>IL-8 Richard Harvey, Germany</b> “Antimicrobial nanomedicines for pulmonary delivery”
11.00-11.30	<b>IL-7 Konstantina Soulele, Greece</b> “Population pharmacokinetics in inhaled drugs”	<b>IL-9 Maria Blanco Prieto, Spain</b> “Nanomedicines in paediatric cancer”
11.30-12.00	<b>OP-3, Nasir Idkaidek, Jordan</b> The use of saliva instead of plasma as a surrogate for drug bioavailability and bioequivalence studies in humans” <b>OP-4, Hristos Glavinas, Hungary</b> Improved bioavailability of a novel abiraterone acetate formulation is driven by immediate transfer of the drug from amorphous nanoparticles to bile micelles followed by its rapid conversion to abiraterone in the intestine”	<b>OP-5, Bruno Sarmiento, Portugal</b> “Engineered albumin variants are promising surface functional moieties to surpass the intestinal barrier for insulin-loaded nanoparticles” <b>OP-6, Sila Gülbağ, Turkey,</b> “Top down production of cyclosporine A nanosuspensions for oral delivery: formulation design and characterization”
12.00-13.30	<b>Lunch break</b>	
<b>Parallel sessions III</b>		
	<b>Drug absorption, dissolution and in-silico modelling – towards prediction paradise?</b>	<b>Manufacturing of future medicines</b>
13.30-14.00	<b>IL-10 Maria Vertzoni, Greece</b> “Advances in biorelevant oral drug product performance testing”	<b>IL-13 Karl-Heinz Seyfang, Germany</b> “Dosing and process control technologies to cover the wide variety of dry powder inhalers”
14.00-14.30	<b>IL-11 Christos Reppas, Greece</b> “Drug absorption from the lower intestine? “	<b>IL-14 Umay Şaplakoğlu, US</b> “Continuous manufacturing of biotech drugs”
14.30-15.00	<b>IL-12 Hartmut Derendorf, US</b> “Modeling and simulation to streamline dose optimization on earth and in space“	<b>IL-15 Sarah Barthold , Germany</b> “Drug delivery in the pediatric and geriatric patient population – Advantages of multiparticulates“
15.00-15.30	<b>Coffee break and Poster Session-3</b>	
<b>Parallel sessions IV</b>		
	<b>Information on drug absorption in regulatory processes: nice-to-know vs. need-to-know</b>	<b>Nanomedicines: from lab to market</b> <i>Organized by EUFEPS Nanomedicine Network</i>
15.30 -16.00	<b>IL-16 Annette Bauer-Brandl, Denmark</b> “In Vitro performance ranking of bioavailability-enhancing oral formulations: Recent advances“	<b>IL-17 Caroline Lemarchand, France</b> “CMC experience in clinical development of nanomedicine”
16.00-16.30	<b>OP-7 Korbinian Löbman, Denmark</b> “In situ amorphization using microwaves. A Potential way to amorphize drug within the final dosage form” <b>OP-8 Gaia Colombo, Italy</b> “Brain and plasma pharmacokinetics of flurbiprofen after nasal powder administration”	<b>IL-18 Rana Sanyal, Turkey</b> “From Synthesis toward Clinical: An experience in Nanomedicine“
16.30-17.00	<b>OP-9 Matej Novak, Czechia</b> “Development of FDM 3D printing as a formulation method for drugs with low bioavailability” <b>OP-10 Sven Stegemann, Austria,</b> “Medicine development for the older and clinically complex patients- closing the gaps to patient centric product design	<b>OP-16 Gamze Varan, Turkey</b> “Evaluation of the apoptotic action mechanism cholesterol targeted amphiphilic cyclodextrin nanoparticles <b>OP-19 Petra Salamunova, Czechia</b> “Research of glucan particles as potential carriers of dilacone for treatment of idiopathic inflammation diseases”
<b>Parallel sessions V</b>		
	<b>EUFEPS Network Pharmacogenetics Research and Implementation (EPRIN)</b>	<b>Biotech and Biosimilars: What is the next step for the future</b>
17.00-17.30	<b>IL-20 Magnus-Ingelman Sundberg, Sweden</b> “Challenges of rare genetic variants in prediction of drug response and adverse drug reactions“	<b>IL-22 Thomas Felix, US</b> Biosimilars: Clinical Relevance of Analytical Structure-Function Studies”
17.30-18.00	<b>IL-21 Andrew Owen, UK</b> “Towards stratified medicine approaches using nanotechnology-based drug delivery systems: A focus on infectious diseases“	<b>IL-23 Ulrike Konrad, Germany</b> “CMC Considerations for Biosimilar Drug Development”
18.00-18.30	<b>OP-11 Kate Bloch, UK</b> “Sequencing in hypersensitivity reactions” <b>OP-12 Paula Perez Pardo, Netherlands</b> “Effects of combined intervention with levodopa and a neurorestorative diet in a mouse model of Parkinson’s disease”	<b>IL-24 Arnold Vulto, Netherlands</b> “Clinical evaluation and interchangeability of biotech products from clinical pharmacist’s point of view”

**Saturday, 26 May 2017**

09.30 - 10.00	<b>PL-5 Sir Munir Pirmohamed, UK, "Personalized medicine in order to optimize drug efficacy and minimize toxicity"</b>		
10.00-10.30	<b>Coffee break and Poster Session 4</b>		
<b>Parallel sessions VI</b>			
	<b>Enhanced Drug Delivery Approaches</b>	<b>Biotech Drugs and Biosimilars Development</b>	<b>Nanotechnology in Health Sciences</b> <i>Organized by</i> <i>EUFEPS Nanomedicine Network</i>
10.30 -11.00	<b>OP-13 Carla Caramella, Italy</b> "Combination products: balancing innovation and technological innovation" <b>OP-14 Flavia Laffleur, Austria</b> "Novel polymeric dosage form for crossing the nail barrier"	<b>IL-25 Despoina Sanoudou, Greece</b> "Genomics and Molecular Biology in drug development and assessment"	<b>IL-28 Devrim Gözüaçık, Turkey</b> "From Cellular Stress Studies to Diagnosis of Diseases using Biochips and Nano Tools"
11.00 -11.30	<b>OP-15 Meritxell Teixido, Spain</b> "Blood-brain barrier shuttle peptides: an emerging tool for brain delivery" <b>OP-25 Seda Rençber, Turkey</b> "Investigations On The Mucoadhesive Hot-Melt Extruded Implants For Treatment Of Vaginal Candidiasis"	<b>IL-26 İrem Yenice, Turkey</b> "Development of a biosimilar monoclonal antibody drug"	<b>OP-20 Silvia Franze, Italy</b> "Novel approaches to prevent drug leakage from deformable liposomes" <b>OP-21 Ayşe Ercan, Turkey</b> "Genomic and metabolomics studies on polycationic amphiphilic cycloextrin nanoparticles on HEPG2 cell line"
11.30-12.00	<b>OP-17 Fakhru Ahsan, US</b> "Multi purpose filaments of HPMC for 3D printing of medications with tailored drug release and timed absorption"	<b>IL-27 Amir Farschi, Iran</b> "MAb development, being fast & furious"	<b>IL-29 Rogerio Gaspar, Portugal,</b> "Nanomedicine and the challenges for integrative healthcare"
12.00-13.30	<b>Lunch break</b>		
<b>Parallel sessions VII</b>			
	<b>EUFEPS Network Systems Pharmacology</b>	<b>New drugs in Oncology</b> <i>German Pharmaceutical Society DPhG</i>	
13.30-14.00	<b>IL-30 Robert Bies, US</b> "On the dilemma of irreproducibility: Inherent or statistical?"	<b>IL-33 Stefan Laufer, Germany</b> "EGFR Triple Mutant: Recent Set-Backs and New Hopes in Fighting Mutant Non-Small Cell Lung Cancer"	<b>OP-23 Angela Fabiano, Italy</b> "Mucoadhesive nanoparticles and oral bioavailability" <b>OP-24 Adryana Clementino, Italy</b> "Mucoadhesion and permeation enhancing of different nanoparticles in excised nasal tissues: a comparative study"
14.00-14.30	<b>IL-31 Aris Dokoumetzidis, Greece</b> "Order reduction of large PBPK and QSP models"	<b>IL-34 Kristian Strømgaard, Sweden</b> "Targeting syntenin and inhibition of cancer"	
14.30-15.00	<b>IL-32 Lars Kuepfer, Germany</b> "Simulating cellular drug responses within a whole-body"	<b>IL-35 Romano Silvestri, Italy</b> "New anti-cancer agents through an interaction with tubulin"	
15.00-15.30	<p align="center"><b>Awards and Closing ceremony</b></p> <p align="center">EJPS Best Paper Award 2017 EUFEPS 2018 Best Poster &amp; Oral Award EUFEPS WIPS Awards EUFEPS Presidential Distinction Awards</p>		